Clinical Trial

Dapagliflozin in Depression

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-15.
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT07239011
Lead Sponsor Tanta University
Conditions Depression
Enrollment 60 participants
Start Date 2025-11-01
Primary Completion 2026-11-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2025-11-25